

# CanREValue

Value-based decisions from Real World Evidence

## Spring 2021 Newsletter

Issue 11 | Spring 2021

### Study Objectives:

#### Objective 1: (ongoing)

- ❖ Develop comprehensive understanding of the current state of RWE nationally & internationally
- ❖ Keep current on emerging/new information related to RWE in Canada and beyond

#### Objective 2: (established & ongoing)

- ❖ Establish formal national working groups dedicated to policy and methodological application of RWE, and collaboratively & iteratively develop a working framework

#### Objective 3: (ongoing)

- ❖ Validate the developed framework through the completion of a multi-province RWE project

#### Objective 4: (ongoing)

- ❖ Employ knowledge translation strategies to establish and integrate the final RWE framework

### CANREVALUE PRESENTING AT #ARCC2021

The [2021 ARCC Conference](#) is being held virtually on May 17<sup>th</sup> and 18<sup>th</sup>, 2021. Featured topics include a discussion on how COVID-19 has impacted cancer care both in Canada and globally, and an exploration of virtual care: looking back and moving forward. More details, including invited speakers, can be found on the conference website at <https://cc-arcc.ca/arcc-conference-2021/>.

CanREValue will be presenting the following work at ARCC2021:

1. Application of Multi-Criteria Decision Analysis for the Prioritization of Real-world Evidence Questions; (Ambica Parmar)
2. Mapping Canadian data assets to conduct real-world studies: lessons learned from CanREValue RWE Data Working Group; (Claire de Oliveira)
3. Real-world cost-effectiveness of pertuzumab with trastuzumab in patients with metastatic breast cancer: population-based patient-level retrospective cohort study conducted by the CanREValue Collaboration; (Wei Fang Dai/Kelvin Chan)

Registration for #ARCC2021 is taking a “Donate What you Can” to the Canadian Cancer Society approach. We hope you can join us there – Register Today at <https://events.eply.com/2021ARCCConference>

Please email Rebecca directly at [Rebecca.Mercer@ontariohealth.ca](mailto:Rebecca.Mercer@ontariohealth.ca) if you have any questions or need additional information about the 2021 ARCC Conference.



## CANREVALUE STAKEHOLDER CONSULTATION – METHODS WORKING GROUP

We are pleased that the public stakeholder consultations regarding the Interim Methods Report developed by the CanREValue Methods Working Groups is now complete.

We received feedback from 13 diverse stakeholders. After carefully considering the feedback, we have developed a response document which is available on our website by [clicking here](#). Based on feedback received, we have also updated the Interim Methods Report itself, the updated version is available by [clicking here](#).

As a reminder, all CanREValue reports and updates are publicly posted on our website at <https://cc-arcc.ca/canrevalue-kt/>.

### WORKING GROUP UPDATES AND NEXT STEPS:

Working Group	Updates & Next Steps
RWE Planning and Drug Selection	<p><b>Updates:</b></p> <ul style="list-style-type: none"><li>• WG Members participated in a teleconference on February 11<sup>th</sup>/12<sup>th</sup> to further develop and refine Steps 1-3 of the CanREValue Framework.</li><li>• Conducted two MCDA workshops (December 2020 and April 2021)</li><li>• Accepted abstract for 2021 ARCC Conference<ul style="list-style-type: none"><li>◦ <i>Application of Multi-Criteria Decision Analysis for the Prioritization of Real-world Evidence Questions; (Ambica Parmar)</i></li></ul></li></ul> <p><b>Next Steps:</b></p> <ul style="list-style-type: none"><li>• Continue assessing the MCDA rating tool. The next MCDA workshop is scheduled for May 2021</li></ul>
RWE Data	<p><b>Updates:</b></p> <ul style="list-style-type: none"><li>• Accepted abstracts for the 2021 ARCC Conference and 2021 ISPOR Conference:<ul style="list-style-type: none"><li>◦ <i>Mapping Canadian data assets to conduct real-world studies: Lessons learned from CanREValue RWE Data Working Group; 2021 ARCC &amp; 2021 ISPOR</i></li><li>◦ <i>Real-world cost-effectiveness of pertuzumab with trastuzumab in patients with metastatic breast cancer: population-based patient-level retrospective cohort study conducted by the CanREValue Collaboration; 2021 ARCC</i></li></ul></li><li>• Held 3 interprovincial meetings with presentations from MB, BC, and ON discussing the analysis</li></ul> <p><b>Next Steps:</b></p> <ul style="list-style-type: none"><li>• Continue with real-world analysis in 9 provinces</li></ul>
RWE Methods	<p><b>Updates:</b></p> <ul style="list-style-type: none"><li>• The updated Interim Methods Working Group report and a Response to Stakeholder Feedback document are now available on the CanREValue website. <a href="#">Click here for the Report</a>. <a href="#">Click here for the Feedback document</a></li></ul> <p><b>Next Steps:</b></p> <ul style="list-style-type: none"><li>• Consult and discuss appropriate methodology for next identified outcome measure</li></ul>



## RWE Reassessment and Uptake

### Updates:

- WG Members participated in a teleconference on November 30<sup>th</sup>/December 8<sup>th</sup>, 2020 to further develop and refine Step 4 of the CanREValue Framework and the RWE Implementation Plan
- Manuscript preparation on the R&U WG and the Mock Reassessment exercise with the WG members

### Next Steps:

- Continue working with WG members and relevant stakeholders to further develop the RWE Implementation Plan

## Stakeholder Engagement

### Updates:

- Held an industry engagement webinar on February 25<sup>th</sup>, 2021 with 15 industry representatives in collaboration with Innovative Medicines Canada (IMC) and BIOTECanada.
- Disseminating and promoting uptake of the Methods Working Group Updated Interim Report and Response to Stakeholder feedback document

### Next Steps:

- Continue to collaborate with IMC and BIOTECanada for future industry engagement opportunities
- Begin planning patient and patient group engagement webinar for Summer 2021

## MEMBER SPOTLIGHT – DR. AVRAM DENBURG, PEDIATRIC ONCOLOGIST

### Dr. Avram Denburg joined the CanREValue Core Team in October 2020 as a Policy Working Group liaison

#### Q: What is your research focused on?

My research is centered on the analysis and strengthening of childhood cancer care systems, with specific focus on issues related to pharmaceutical policy and drug access for children in Canada and internationally. I am lucky to have a wonderful team in my lab at SickKids Research Institute that is engaged in projects on HTA and cancer drug access in various health system contexts globally. Current priority areas of research include: development of novel approaches for value-based assessment of pediatric health technologies, including precision cancer therapies; incorporation of societal values and public preferences into HTA and pharmaceutical policy; comparative analysis of policy approaches to precision cancer therapy regulation and reimbursement; and analysis of cancer drug availability, cost, and access dynamics in a range of low- and middle-income countries.



#### Q: What is your educational background and how did it lead to an interest in RWE?

I am a pediatric oncologist, a health system researcher with doctoral training in health policy, and a member of pCODR's Expert Review Committee and the Ontario Steering Committee on Cancer Drugs. These various roles have afforded me a multifaceted view of the scholarly and practical aspects of HTA in Canada, including areas of strengths and opportunities for innovation. I see RWE as a crucial component of HTA in an evolving era of



assessment, and coverage.

**Q: What aspect of the CanREValue project are you the most excited to work on?**

I feel very privileged to be part of the CanREValue team and am especially excited about the opportunity to work on implementing its vision for real-world evidence generation and appraisal *in the real-world!* A tremendous amount of work has gone into developing a robust and system-tailored RWE program for Canada. Incorporating this program into Canadian health systems will require engagement with key institutional stakeholders and policy decision-makers to ensure it is fit to purpose, iterative assessment of its design and implementation to support sustained uptake, and stewardship of its transition into real-world use. I'm hopeful I can help realize these goals in my role as Policy Working Group Liaison for the project.

**Q: What are some of your personal hobbies?**

I'm not sure one's children can count as hobbies, but my three boys have certainly required more than the 10,000 hours required for expertise...though am still far from an 'expert' parent. I love running and am always looking for new trails, local and far-flung. My love of running is equaled only by my love of food – a delicate balance. My cooking is passable, but I'm counting on a post-COVID restaurant resurgence!

**Q: How can we reach you? [Avram.denburg@sickkids.ca](mailto:Avram.denburg@sickkids.ca)****Recent Publications/Presentations:****Publications:**

Dai WF, Beca J, Croxford R, Isaranuwachai W, Menjak IB, Petrella TM, Mittmann N, Earle CC, Gavura S, Mercer RE, Hanna TP, Chan KKW. [Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada](#). Int J Cancer. 2021 Apr 15; 148(8):1910-1918.

Naipaul RD, Mercer RE, Chan KKW, Yeung L, Forbes L, Gavura S. [Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario](#). Curr. Oncol. 2021, 28(2):1056-1066.

